Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound and application thereof in preparing drug for curing viral respiratory infection

The technology of a compound and a drug is applied in the preparation of a drug for treating respiratory virus infection.

Inactive Publication Date: 2010-07-28
崔坤元 +1
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0014] There is no report on the preparation of alkyaryl polyether alcohols for the preparation of anti-respiratory virus drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound and application thereof in preparing drug for curing viral respiratory infection
  • Compound and application thereof in preparing drug for curing viral respiratory infection
  • Compound and application thereof in preparing drug for curing viral respiratory infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064]Human airway epithelial tissue cells were planted on a support mesh made of nylon and allowed to grow at the liquid-air interface. It was cultivated as a modified Ex-Cell Vero serum-free medium (purchased from Invitrogen). PR8 influenza virus was infected on the surface of respiratory epithelial tissue for 4 hours, and then directly administered (spray administration) through the surface of the tissue or added Tyloxapol (compound A) or neutral control (compound C) and positive control (Tamiflu ) (liquid administration). according to Figure 1-7 After treatment for the indicated time, the samples were collected, RNA was isolated and the virus was quantified by quantitative RT-PCR method. At the same time, the culture fluid was collected to detect LDH for toxicity analysis. see results Figure 1-7 .

Embodiment 2

[0066] After the mouse is lightly anesthetized, it is used to erect the mouse with its nose up, and then use a micropipette to transfer the PR8 virus

[0067] (2000pfu / 300μl in PBS) was dripped into the external nostril of the mouse to inhale, and the mouse was kept upright for 5 seconds to ensure that the mouse sucked all the solution into the trachea. Then use a warming lamp to keep the mouse warm for about 20 minutes or until the mouse resumes its activities. After the mouse is infected with the influenza virus for 24 hours, use the above method to drip 50 μl 4mg / mL Tyloxapol solution into the mouse through the nasal passage. The dose of Tamiflu is 10mg / kg, the untreated group and the PBS nutrient solution group were used as controls (except the untreated group, each group was given an equal volume of the corresponding solution twice a day), and the lungs of the mice were taken after 96 hours of infection, and the RNA was isolated and analyzed by quantitative RT-PCR. Method...

Embodiment 3

[0069] Dissolve Calixarenes in 0.9% sodium chloride solution, adjust the pH to about 7.0 with NaOH or HCl, and use 0.9% sodium chloride solution to make the final concentration 4mg / ml. After the mice were lightly anesthetized, the mice were erected with their noses up, and then the PR8 virus (2000pfu / 300μl in PBS) was dripped into the external nostrils of the mice with a micropipette for inhalation, and the mice were kept upright for 5 seconds while ensuring that the mouse draws all the solution into the trachea. Then use a warming lamp to keep the mice warm for about 20 minutes or until the mice resume their activities. 24 hours after the mice are infected with the influenza virus, use the above method to instill 50 μl of 4mg / ml Calixarenes (calixarenes) solution into the mice through the nasal passages , the dose of Tamiflu is 10mg / kg body weight, the infection untreated group and the PBS nutrient solution group are the controls (except the untreated group, each group is giv...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of pharmacy, disclosing a compound and application thereof in preparing a drug for curing viral respiratory infection. The compound comprises the following structural formula shown in a formula (I), wherein R is-CH2-CH2-, R' is linear chain or multiple-chain alkyl of C4-C14, x is 1-50, and y is 0-50. The compound has the effect of resisting respiratory system viral infection and can be used for preparing the drug for treating respiratory system viral infection.

Description

technical field [0001] The invention belongs to the field of pharmacy, and relates to a compound and its application in preparing medicine for treating respiratory virus infection. Background technique [0002] Respiratory viral infection is common in people of all ages. It is a common disease in both adults and children. There is currently no effective treatment. Most infections are relatively mild and self-limited and limited to the upper respiratory tract. These viral infections It can be serious, like the flu, or it can be a mild, self-limited infection that gets better in a few days. Common viruses that cause respiratory infections include Rhinovirus, Para-lnfluenza, Coronavirus, Respiratory syncytial virus, Influenza Virus, Enterovirus and certain These viruses can cause different respiratory infections and complications: such as common cold, sinusitis, bronchitis, pneumonia and otitis media. Many viral infections also often induce bacterial infections. This secondary...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C08G65/34A61P31/16A61P31/14A61P31/20A61K31/765A61P31/12A61P11/00
Inventor 崔坤元梁东
Owner 崔坤元
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com